Form 4: Tandem Diabetes Director Equity Vesting and Grant

Director Joao Paulo Falcao Malagueira acquired 8,759 shares via RSU vesting and received a new grant of 10,220 RSUs.

Summary

• Director Joao Paulo Falcao Malagueira vested 8,759 restricted stock units (RSUs) on May 21, 2026.
• The director received a new grant of 10,220 RSUs on May 20, 2026, under the 2023 Long-Term Incentive Plan.
• Following these transactions, the director holds 22,458 shares of common stock.
• The new RSU grant is scheduled to vest on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation and equity ownership, which carries no significant market sentiment impact.

Positives

• Director maintains a significant equity stake of 22,458 shares, aligning interests with shareholders.

Negatives

• None noted.

Risks

• Future vesting of RSUs is subject to the terms of the 2023 Long-Term Incentive Plan.

Future Outlook

The newly granted 10,220 RSUs are scheduled to vest on May 20, 2027, subject to the terms of the 2023 Long-Term Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants and vesting schedules for directors are standard corporate governance practices in the medical device sector, intended to incentivize long-term retention and performance alignment.

Comparison to Industry Standards

• The use of RSUs as a primary component of director compensation is consistent with standard practices for mid-cap medical technology companies.
• The one-year vesting cycle for director equity is common among peers in the healthcare sector.

Corporate Governance

Stakeholder Impact

• Minimal impact on stakeholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 10,220 RSUs granted on May 20, 2026, expected on May 20, 2027.

Key Dates

Keywords

Tandem Diabetes Care, TNDM, Form 4, Insider Trading, Equity Compensation, Director Ownership